Zeke Capital Advisors LLC lowered its position in Boston Scientific Co. (NYSE:BSX) by 10.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 18,580 shares of the medical equipment provider’s stock after selling 2,231 shares during the period. Zeke Capital Advisors LLC’s holdings in Boston Scientific were worth $799,000 as of its most recent SEC filing.
Several other hedge funds also recently bought and sold shares of the company. First Quadrant L P CA lifted its holdings in shares of Boston Scientific by 126.6% in the second quarter. First Quadrant L P CA now owns 87,906 shares of the medical equipment provider’s stock valued at $3,778,000 after purchasing an additional 49,113 shares in the last quarter. Greenleaf Trust increased its position in shares of Boston Scientific by 5.1% during the second quarter. Greenleaf Trust now owns 10,320 shares of the medical equipment provider’s stock valued at $444,000 after acquiring an additional 502 shares during the last quarter. Westside Investment Management Inc. purchased a new stake in shares of Boston Scientific during the second quarter valued at approximately $31,000. BB&T Corp increased its position in shares of Boston Scientific by 0.5% during the second quarter. BB&T Corp now owns 52,968 shares of the medical equipment provider’s stock valued at $2,277,000 after acquiring an additional 288 shares during the last quarter. Finally, Commerzbank Aktiengesellschaft FI increased its position in shares of Boston Scientific by 22.1% during the second quarter. Commerzbank Aktiengesellschaft FI now owns 56,286 shares of the medical equipment provider’s stock valued at $2,419,000 after acquiring an additional 10,172 shares during the last quarter. Institutional investors own 90.66% of the company’s stock.
A number of analysts recently commented on BSX shares. Evercore ISI raised Boston Scientific from an “in-line” rating to an “outperform” rating and set a $36.20 price target for the company in a research report on Monday, May 13th. Wells Fargo & Co increased their price target on Boston Scientific from $42.00 to $45.00 and gave the company an “outperform” rating in a research report on Tuesday, June 18th. Jefferies Financial Group increased their price target on Boston Scientific from $44.00 to $48.00 and gave the company a “positive” rating in a research report on Thursday, June 27th. Canaccord Genuity increased their price target on Boston Scientific from $43.00 to $46.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Finally, Raymond James increased their price target on Boston Scientific from $48.00 to $50.00 and gave the company a “strong-buy” rating in a research report on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $44.91.
NYSE:BSX traded up $0.66 during trading hours on Tuesday, reaching $42.02. The stock had a trading volume of 119,880 shares, compared to its average volume of 6,059,719. The company has a current ratio of 1.31, a quick ratio of 1.04 and a debt-to-equity ratio of 0.81. The stock has a 50 day moving average of $42.32. Boston Scientific Co. has a 12-month low of $31.56 and a 12-month high of $43.66. The firm has a market capitalization of $58.35 billion, a PE ratio of 28.63, a P/E/G ratio of 2.56 and a beta of 0.80.
Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.39 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.38 by $0.01. Boston Scientific had a return on equity of 23.29% and a net margin of 13.85%. The business had revenue of $2.63 billion during the quarter, compared to the consensus estimate of $2.64 billion. During the same period last year, the business posted $0.41 earnings per share. The business’s revenue for the quarter was up 5.7% on a year-over-year basis. As a group, equities research analysts expect that Boston Scientific Co. will post 1.56 earnings per share for the current year.
Boston Scientific Company Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.